Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

NCT04989322 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Nsclc
EGFR Activating Mutation
EGF-R Positive Non-Small Cell Lung Cancer
ALK Gene Rearrangement Positive
ROS1 Gene Rearrangement
ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

Dr Joanne CHIU